Torii Pharmaceutical Co Ltd
TSE:4551

Watchlist Manager
Torii Pharmaceutical Co Ltd Logo
Torii Pharmaceutical Co Ltd
TSE:4551
Watchlist
Price: 4 570 JPY -0.44% Market Closed
Market Cap: 131.6B JPY

Torii Pharmaceutical Co Ltd
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Torii Pharmaceutical Co Ltd
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Torii Pharmaceutical Co Ltd
TSE:4551
Net Issuance of Common Stock
-ÂĄ2m
CAGR 3-Years
N/A
CAGR 5-Years
-15%
CAGR 10-Years
-7%
Takeda Pharmaceutical Co Ltd
TSE:4502
Net Issuance of Common Stock
-ÂĄ1.9B
CAGR 3-Years
67%
CAGR 5-Years
13%
CAGR 10-Years
20%
Daiichi Sankyo Co Ltd
TSE:4568
Net Issuance of Common Stock
-ÂĄ191.8B
CAGR 3-Years
-47%
CAGR 5-Years
-380%
CAGR 10-Years
-146%
Otsuka Holdings Co Ltd
TSE:4578
Net Issuance of Common Stock
-ÂĄ50B
CAGR 3-Years
-3 584%
CAGR 5-Years
-771%
CAGR 10-Years
N/A
Chugai Pharmaceutical Co Ltd
TSE:4519
Net Issuance of Common Stock
ÂĄ148m
CAGR 3-Years
-22%
CAGR 5-Years
-27%
CAGR 10-Years
-19%
Astellas Pharma Inc
TSE:4503
Net Issuance of Common Stock
-ÂĄ7B
CAGR 3-Years
8%
CAGR 5-Years
41%
CAGR 10-Years
14%

Torii Pharmaceutical Co Ltd
Glance View

Market Cap
128.5B JPY
Industry
Pharmaceuticals

Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 560 full-time employees. The company went IPO on 2013-10-01. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.

Intrinsic Value
4 709.68 JPY
Undervaluation 3%
Intrinsic Value
Price

See Also

What is Torii Pharmaceutical Co Ltd's Net Issuance of Common Stock?
Net Issuance of Common Stock
-2m JPY

Based on the financial report for Dec 31, 2024, Torii Pharmaceutical Co Ltd's Net Issuance of Common Stock amounts to -2m JPY.

What is Torii Pharmaceutical Co Ltd's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
-7%

Back to Top